References for Peak K2 - Menatetranone:

For article - Click Here

1 “Vitamin K.” In: Scientific Review Committee. Nutrition recommendations: report of the
Scientific Review Committee. Ottawa, ON: Minister of National Health & Welfare Canada.
1990; H49-42/1990E: 97-8.
2 Ronden JE, Thijssen HH, Vermeer C. Tissue distribution of K-vitamers under different
nutritional regimens in the rat. Biochim Biophys Acta. 1998 Jan 8;1379(1):16-22.
3 Groenen-van Dooren MM, Soute BA, Jie KS, Thijssen HH, Vermeer C. The relative effects of
phylloquinone and menaquinone-4 on the blood coagulation factor synthesis in vitamin
K-deficient rats. Biochem Pharmacol. 1993 Aug 3;46(3):433-7.
4 Booth SL, Tucker KL, Chen H, Hannan MT, Gagnon DR, Cupples LA, Wilson PW, Ordovas J,
Schaefer EJ, Dawson-Hughes B, Kiel DP. Dietary vitamin K intakes are associated with hip
fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000
May;71(5):1201-8.
5 Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip
fractures in women: a prospective study. Am J Clin Nutr. 1999 Jan;69(1):74-9.
6 Hart JP, Shearer MJ, Klenerman L, Catterall A, Reeve J, Sambrook PN, Dodds RA, Bitensky L,
Chayen J. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis.
J Clin Endocrinol Metab. 1985 Jun;60(6):1268-9.
7 Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O’Fallon WM, Castro MR, Melton LJ 3rd.
Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999 Aug 9-
23;159(15):1750-6.
8 Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in
elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1998 May
15;128(10):829-32.
9 Haffa A, Krueger D, Bruner J, Engelke J, Gundberg C, Akhter M, Binkley N. Diet- or warfarininduced
vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without
altering skeletal status in growing female rats. J Bone Miner Res. 2000 May;15(5):872-8.
10 Craciun AM, Groenen-van Dooren MM, Thijssen HH, Vermeer C. Induction of prothrombin
synthesis by K-vitamins compared in vitamin K-deficient and in brodifacoum-treated rats. Biochim
Biophys Acta. 1998 Mar 12;1380(1):75-81.
11 Groenen-van Dooren MM, Soute BA, Jie KS, Thijssen HH, Vermeer C. The relative effects of
phylloquinone and menaquinone-4 on the blood coagulation factor synthesis in vitamin K-deficient
rats. Biochem Pharmacol. 1993 Aug 3;46(3):433-7.
12 Sato T, Ohtani Y, Yamada Y, Saitoh S, Harada H. Difference in the metabolism of vitamin K
between liver and bone in vitamin K-deficient rats. Br J Nutr. 2002 Apr;87(4):307-14.
13 Sano Y, Tadano K, Kaneko K, Kikuchi K, Yuzuriha T. Distribution of menaquinone-4, a therapeutic
agent for osteoporosis, in bone and other tissues of rats. J Nutr Sci Vitaminol (Tokyo).
1995 Oct;41(5):499-514.
14 Thijssen HH, Drittij-Reijnders MJ, Fischer MA. Phylloquinone and menaquinone-4 distribution
in rats: synthesis rather than uptake determines menaquinone-4 organ concentrations. J Nutr.
1996 Feb;126(2):537-43.
15 Thijssen HH, Baars LG. Tissue distribution of selective warfarin binding sites in the rat.
Biochem Pharmacol. 1991 Nov 6;42(11):2181-6.
16 Vermeer C, Hendrix H, Daemen M. Vitamin K-dependent carboxylases from non-hepatic tissues.
FEBS Lett. 1982 Nov 8;148(2):317-20.
17 Friedman PA, Smith MW. A survey of rat tissues for phylloquinone epoxidase activity.
Biochem Pharmacol. 1977 Apr 15;26(8):804-5.
18 Hodges SJ, Pilkington MJ, Stamp TC, Catterall A, Shearer MJ, Bitensky L, Chayen J.
Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine
and femoral neck. Bone. 1991;12(6):387-9.
19 Kaneki M, Mizuno Y, Hosoi T, Inoue S, Hoshino S, Akishita M, Akedo Y, Horiki K, Nakamura
T, Shiraki M, et al. Serum concentration of vitamin K in elderly women with involutional osteoporosis.
Nippon Ronen Igakkai Zasshi. 1995 Mar;32(3):195-200.
20 Kanai T, Takagi T, Masuhiro K, Nakamura M, Iwata M, Saji F. Serum vitamin K level and bone
mineral density in post-menopausal women. Int J Gynaecol Obstet. 1997 Jan;56(1):25-30.
21 Tamatani M, Morimoto S, Nakajima M, Fukuo K, Onishi T, Kitano S, Niinobu T, Ogihara T.
Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men.
Metabolism. 1998 Feb;47(2):195-9.
22 Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1
and K2 decreased in elderly women with hip fracture. J Bone Miner Res1993Oc;8(10):1241-5.
23 Kaneki M, Hedges SJ, Hosoi T, Fujiwara S, Lyons A, Crean SJ, Ishida N, et al. Japanese
fermented soybean food as the major determinant of the large geographic difference in
circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition. 2001
Apr;17(4):315-21.
24 Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect
of food matrixon circulating vitamin K concentrations. Haemostasis. 2000 Nov-Dec;30(6):298-
307.
25 Orimo H, Hosoda Y, Fujiwara S, Mizuno S, Hashimoto T, Tamaki T, Nose T, Yamamoto K,
Sasaki R. Fracture incidence in Japan. J Bone Miner Metab. 1991 Aug;9(Supp):89-93. Cited in
(23).
26 Orimo H, Hashimoto T, Shiraki M, et al. Nation-wide survey of hip fracture incidence in
Japan. Jpn Med J. 1995;3707:27. Cited in (23).
27 Hara K, Akiyama Y, Tajima T, Shiraki M. Menatetrenone inhibits bone resorption partly
through inhibition of PGE2 synthesis in vitro. J Bone Miner Res. 1993 May;8(5):535-42.
28 Hara K, Akiyama Y, Nakamura T, Murota S, Morita I. The inhibitory effect of vitamin K2
(menatetrenone) on bone resorption may be related to its side chain. Bone. 1995
Feb;16(2):179-84.
29 Koshihara Y, Hoshi K, Shiraki M. Vitamin K2 (menatetrenone) inhibits prostaglandin synthesis
in cultured human osteoblast-like periosteal cells by inhibiting prostaglandin H synthase activity.
Biochem Pharmacol. 1993 Oct 19;46(8):1355-62.
30 Takeuchi Y, Suzawa M, Fukumoto S, Fujita T. Vitamin K(2) inhibits adipogenesis, osteoclastogenesis,
and ODF/RANK ligand expression in murine bone marrow cell cultures. Bone. 2000
Dec;27(6):769-76.
31 Kameda T, Miyazawa K, Mori Y, Yuasa T, Shiokawa M, Nakamaru Y, Mano H, Hakeda Y,
Kameda A, Kumegawa M. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast
apoptosis. Biochem Biophys Res Commun. 1996 Mar 27;220(3):515-9.
32 Kawata T, Zernik JH, Fujita T, Tokimasa C, Tanne K. Mechanism in inhibitory effects of vitamin
K2 on osteoclastic bone resorption: in vivo study in osteopetrotic (op/op) mice. J Nutr Sci
Vitaminol (Tokyo). 1999 Aug;45(4):501-7.
33 Urayama S, Kawakami A, Nakashima T, Tsuboi M, Yamasaki S, Hida A, Ichinose Y,
Nakamura H, Ejima E, Aoyagi T, Nakamura T, Migita K, Kawabe Y, Eguchi K. Effect of vitamin
K2 on osteoblast apoptosis: vitamin K2 inhibits apoptotic cell death of human osteoblasts
induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J Lab Clin Med. 2000
Sep;136(3):181-93.
34 Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular
matrix of human osteoblasts in vitro. J Bone Miner Res. 1997 Mar;12(3):431-8.
35 Yamaguchi M, Sugimoto E, Hachiya S. Stimulatory effect of menaquinone-7 (vitamin K2) on
osteoblastic bone formation in vitro. Mol Cell Biochem. 2001 Jul;223(1-2):131-7.
36 Wang X, Wu J, Shidoji Y, Muto Y, Ohishi N, Yagi K, Ikegami S, Shinki T, Udagawa N, Suda
T, Ishimi Y. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and
inhibition of osteoclast formation. J Bone Miner Res. 2002 Jan;17(1):91-100.
37 Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G,
Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate
in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption,
and kinase activation in vitro. PNAS. 1999 Jan 5;96(1):133-8.
38 Hoshi K, Nomura K, Sano Y, Koshihara Y. Nuclear vitamin K2 binding protein in human
osteoblasts: homologue to glyceraldehyde-3-phosphate dehydrogenase. Biochem Pharmacol.
1999 Nov 15;58(10):1631-8.
39 Bach AU, Anderson SA, Foley AL, Williams EC, Suttie JW. Assessment of vitamin K status in
human subjects administered “minidose” warfarin. Am J Clin Nutr. 1996 Dec;64(6):894-902.
40 Sokoll LJ, O’Brien ME, Camilo ME, Sadowski JA. Undercarboxylated osteocalcin and development
of a method to determine vitamin K status. Clin Chem. 1995 Aug;41(8 Pt 1):1121-8.
41 Mawatari T, Muira H, Moro-oka T, Kawano T, Higaki H, Karamura H, Iwamoto Y. Effect of
delayed therapeutic intervention with vitamin K2 after trabecular connectivity was lost in ovariectomized
rats. J Bone Miner Res. 2000 Sep;15(Suppl 1):S308(AbsSA401).
42 Xin F, Takemitsu M, Atsuta Y. Effect of vitamin K(2) on lumbar vertebral bone: histomorphometric
analyses in experimental osteoporotic rats. J Orthop Sci. 2001;6(6):535-9.
43 Mawatari T, Miura H, Higaki H, Moro-Oka T, Kurata K, Murakami T, Iwamoto Y. Effect of
vitamin K2 on three-dimensional trabecular microarchitecture in ovariectomized rats. J Bone
Miner Res. 2000 Sep;15(9):1810-7.
44 Yamaguchi M, Kakuda H, Gao YH, Tsukamoto Y. Prolonged intake of fermented soybean
(natto) diets containing vitamin K2 (menaquinone-7) prevents bone loss in ovariectomized rats.
J Bone Miner Metab. 2000;18(2):71-6.
45 Akiyama Y, Hara K, Kobayashi M, Tomiuga T, Nakamura T. Inhibitory effect of vitamin K2
menatetrenone) on bone resorption in ovariectomized rats: a histomorphometric and dual energy
X-ray absorptiometric study. Jpn J Pharmacol. 1999 May;80(1):67-74.
46 Yamaguchi M, Taguchi H, Gao YH, Igarashi A, Tsukamoto Y. Effect of vitamin K2
(menaquinone-7) in fermented soybean (natto) on bone loss in ovariectomized rats. J Bone Miner
Metab. 1999;17(1):23-9.
47 Akiyama Y, Hara K, Ohkawa I, Tajima T. Effects of menatetrenone on bone loss induced by
ovariectomy in rats. Jpn J Pharmacol. 1993 Jun;62(2):145-53.
48 Tomiuga T, Akiyama Y, Kobayashi M, Hara K, Kawashima H. Vitamin K2 (menatetrenone)
treatment increased bone strength in rats given low-calcium diets. Nippon Yakurigaku Zasshi.
1999 Nov;114(5):303-13.
49 Hara K, Akiyama Y, Ohkawa I, Tajima T. Effects of menatetrenone on prednisolone-induced
bone loss in rats. Bone. 1993 Nov-Dec;14(6):813-8.
50 Onodera K, Takahashi A, Sakurada S, Okano Y. Effects of phenytoin and/or vitamin K2
(menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci. 2002 Feb
15;70(13):1533-42.
51 Shiomi S, Nishiguchi S, Kubo S, Tamori A, Habu D, Takeda T, Ochi H. Vitamin K2 (menatetrenone)
for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol. 2002
Apr;97(4):978-81.
52 Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence
of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the
effect of etidronate. J Orthop Sci. 2001;6(6):487-92.
53 Inoue T, Sugiyama T, Matsubara T, Kawai S, Furukawa S. Inverse correlation between the
changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin
K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. Endocr J.
2001 Feb;48(1):11-8.
54 Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T, Kubo S. Randomized pilot
trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol. 2001
Oct;35(4):543-5.
55 Bunyaratavej N, Penkitti P, Kittimanon N, Boonsangsom P, Bonjongsat A, Yunoi S. Efficacy
and safety of menatetrenone-4 postmenopausal Thai women. J Med Assoc Thai. 2001 Oct;84
Suppl 2:S553-9.
56 Iwamoto J, Takeda T, Ichimura S. Effect of combined administration of vitamin D3 and vitamin
K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
J Orthop Sci. 2000;5(6):546-51.
57 Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on
prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis.
Calcif Tissue Int. 2000 Feb;66(2):123-8.
58 Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures
and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000
Mar;15(3):515-21.
59 Sugiyama T, Saito Y, Kaichi I, Sugi M, Tanaka H, Kawai S. Menatetrenone plus alfacalcidol
treatment for bone problems in eight children with skeletal unloading. J Bone Miner Metab.
2000;18(1):41-4.
60 Somekawa Y, Chigughi M, Harada M, Ishibashi T. Use of vitamin K2 (menatetrenone) and
1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. J Clin Endocrinol
Metab. 1999 Aug;84(8):2700-4.
61Iwamoto I, Kosha S, Noguchi S, Murakami M, Fujino T, Douchi T, Nagata Y. A longitudinal
study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative
study with vitamin D3 and estrogen-progestin therapy. Maturitas 1999Jan4;31(2):161-4.
62 Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. Effects of menatetrenone on the
bone and mineral metabolism in osteoporosis: a double-blind placebo-controlled trial. J Bone
Miner Metab. 1998;16(2):106-12.
63 Tsuji H, Honke K, Hasui M. Effects of a vitamin K2 preparation in severely handicapped
patients complicated by osteopenia. No To Hattatsu. 1998 Nov;30(6):477-82.
64 Sato Y, Honda Y, Kuno H, Oizumi K. Menatetrenone ameliorates osteopenia in disuseaffected
limbs of vitamin D- and K-deficient stroke patients. Bone. 1998 Sep;23(3):291-6.
65 Orimo H, Fujita T, Onomura T, Inoue T, Kushida K, Shiraki M. Clinical evaluation of Ea-0167
(menatetrenone) in the treatment of osteoporosis. Phase III double-blind multicenter comparative
study with alfacalcidol. Clin Eval. 1992;20(1):45-100.
66 Orimo H, Shiraki M, Fujita T, Onomura T, Inoue T, Kushida K. Clinical evaluation of menatetrenone
in the treatment of involutional osteoporosis – a double-blind multicenter comparative
study with 1-alpha-hydroxy vitamin D3. J Bone Miner Res. 1992 Aug;7(Suppl1):S122(118).
67 Hattori M, Morita N, Tsujino Y, Yamamoto M, Tanizawa T. Vitamins D and K in the treatment
of osteoporosis secondary to graft-versus-host disease following bone-marrow transplantation.
J Int Med Res. 2001 Jul-Aug;29(4):381-4.
68 Shiraki M. Vitamin K2 effects on the risk of fractures and on lumbar bone mineral density in
osteoporosis – a randomized prospective 3-year study. Osteoporos Int. 2002 Apr;13(Suppl
1):S160 (Abs SY29).
69 Asakura H, Myou S, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, Yamazaki M,
Nakao S. Vitamin K administration to elderly patients with osteoporosis induces no hemostatic
activation, even in those with suspected vitamin K deficiency. Osteoporos Int. 2001
Dec;12(12):996-1000.
70 Schurgers LJ, Shearer MJ, Hamulyak K, Vermeer C. Effect of dietary vitamin K on stability of
oral anticoagulan therapy: dose-response relationships in healthy subjects. Thromb Haemost.
2001 Jul;85(Suppl):P769.
71 Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality.
Osteoporos Int. 2002;13(2):97-104.
72 Parfitt AM. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am
J Med. 1987 Jan 26;82(1B):68-72.
73 Consensus development conference. Diagnosis, prophylaxis, and treatment of osteoporosis.
Am J Med. 1993 Jun;94(6):646-50.
74 Marcus R, Majumder S. The nature of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds).
Osteoporosis. Second Edition. 2001; New York, NY: Academic Press, Vol 2, pp 3-17.
74a World Health Organization. Study Group on Assessment of Fracture Risk and Its
Application to Screening and Postmenopausal Osteoporosis. Report of a WHO Study Group.
Technical Report Series Number 84. 1994;Geneva: WHO.
75 Marcelli C, Meunier PJ. Fluoride therapy. Influence on the microarchitecture and biomechanical
properties of bone. Presse Med. 1994 Oct 1;23(29):1344-8.
76 Sogaard CH, Mosekilde L, Richards A, Mosekilde L. Marked decrease in trabecular bone
quality after five years of sodium fluoride therapy – assessed by biomechanical testing of iliac
crest bone biopsies in osteoporotic patients. Bone. 1994 Jul-Aug;15(4):393-9.
77 Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment
of postmenopausal osteoporotic fractures: a meta-analysis Osteoporos Int 2000;11(9):727-38.
78 Riggs BL, Hodgson SF, O’Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ
3rd. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
N Engl J Med. 1990 Mar 22;322(12):802-9.
79 Hedlund LR, Gallagher JC. Increased incidence of hip fracture in osteoporotic women treated
with sodium fluoride. J Bone Miner Res. 1989 Apr;4(2):223-5.
80 Rosen CJ, Bilezikian JP. Clinical review 123: Anabolic therapy for osteoporosis. J Clin
Endocrinol Metab. 2001 Mar;86(3):957-64.
81 Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization
of bone: therapeutic implications. Bone. 1997 Nov;21(5):373-7.
82 Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone
turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical
properties in dog rib. J Bone Miner Res. 2000 Apr;15(4):613-20.
83 Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA,
Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of
alendronate on risk of fracture in women with low bone density but without vertebral fractures:
results from the Fracture Intervention Trial. JAMA. 1998 Dec 23-30;280(24):2077-82.
84 Heaney RP. Bone mass, bone fragility, and the decision to treat. JAMA. 1998 Dec 23-
30;280(24):2119-20.
85 Netelenbos C. Osteoporosis: intervention options. Maturitas. 1998 Nov 16;30(3):235-9.
86 Wimalawansa SJ. Prevention and treatment of osteoporosis: efficacy of combination of hormone
replacement therapy with other antiresorptive agents. J Clin Densitom. 2000
Summer;3(2):187-201.
87 Vermeer C, Jie KS, Knapen MH. Role of vitamin K in bone metabolism. Annu Rev Nutr.
1995;15:1-22.
88 Groenen-van Dooren MM, Ronden JE, Soute BA, Vermeer C. Bioavailability of phylloquinone
and menaquinones after oral and colorectal administration in vitamin K-deficient rats. Biochem
Pharmacol. 1995 Sep 7;50(6):797-801.
89 Ichihashi T, Takagishi Y, Uchida K, Yamada H. Colonic absorption of menaquinone-4 and
menaquinone-9 in rats. J Nutr. 1992 Mar;122(3):506-12.
90 Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr.
1995;15:399-417.
91 Igarashi O. Vitamin K. Nippon Rinsho. 1993 Apr;51(4):910-8.
92 Shearer MJ. Vitamin K. Lancet. 1995 Jan 28;345(8944):229-34.
93Koivu-Tikkanen TJ, Schurgers LJ, Thijssen HH, Vermeer C. Intestinal, hepatic, and circulating
vitamin K levels at low and high intakes of vitamin K in rats. Br J Nutr 2000 Feb;83(2):185-90.
94 Gijsbers BL, Jie KS, Vermeer C. Effect of food composition on vitamin K absorption in human
volunteers. Br J Nutr. 1996 Aug;76(2):223-9.
95 Huber AM, Davidson KW, O’Brien-Morse ME, Sadowski JA. Tissue phylloquinone and
menaquinones in rats are affected by age and gender. J Nutr. 1999 May;129(5):1039-44.
96 Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002 Jun
8;359(9322):2018-26.
97 Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr
Metab Care. 2001 Nov;4(6):483-7.